Pfizer Inc. (NYSE:PFE) Shares Sold by PFS Partners LLC

PFS Partners LLC reduced its stake in shares of Pfizer Inc. (NYSE:PFE) by 11.2% during the 4th quarter, according to its most recent filing with the SEC. The firm owned 3,688 shares of the biopharmaceutical company’s stock after selling 465 shares during the period. PFS Partners LLC’s holdings in Pfizer were worth $98,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Retirement Wealth Solutions LLC acquired a new stake in Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its stake in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 38,015 shares during the last quarter. Quarry LP purchased a new position in shares of Pfizer during the 2nd quarter worth $31,000. Teachers Insurance & Annuity Association of America acquired a new position in shares of Pfizer during the 3rd quarter valued at about $35,000. Finally, Joseph Group Capital Management increased its position in Pfizer by 168.3% during the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 771 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Guggenheim cut their price target on shares of Pfizer from $35.00 to $33.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Cantor Fitzgerald restated an “overweight” rating and issued a $45.00 target price on shares of Pfizer in a research report on Wednesday, October 23rd. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 20th. Bank of America reaffirmed a “neutral” rating and issued a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Finally, UBS Group decreased their price objective on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Stock Performance

Pfizer stock opened at $26.23 on Tuesday. The company has a market capitalization of $148.62 billion, a price-to-earnings ratio of 35.44, a price-to-earnings-growth ratio of 0.66 and a beta of 0.64. Pfizer Inc. has a 12-month low of $24.48 and a 12-month high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm’s fifty day moving average price is $26.27 and its 200 day moving average price is $27.85.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. On average, research analysts forecast that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be given a $0.43 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.42. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.56%. The ex-dividend date of this dividend is Friday, January 24th. Pfizer’s dividend payout ratio (DPR) is presently 232.44%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.